Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
Glucagon is historically described as the counterregulatory hormone to insulin, induced by fasting/hypoglycemia to raise blood glucose through action mediated in the liver. However, it is becoming clear that the biology of glucagon is much more complex and extends beyond hepatic actions to exert con...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2020-04, Vol.69 (4), p.532-541 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 541 |
|---|---|
| container_issue | 4 |
| container_start_page | 532 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 69 |
| creator | Finan, Brian Capozzi, Megan E Campbell, Jonathan E |
| description | Glucagon is historically described as the counterregulatory hormone to insulin, induced by fasting/hypoglycemia to raise blood glucose through action mediated in the liver. However, it is becoming clear that the biology of glucagon is much more complex and extends beyond hepatic actions to exert control on glucose metabolism. We discuss the inconsistencies with the canonical view that glucagon is primarily a hyperglycemic agent driven by fasting/hypoglycemia and highlight the recent advances that have reshaped the metabolic role of glucagon. These concepts are placed within the context of both normal physiology and the pathophysiology of disease and then extended to discuss emerging strategies that incorporate glucagon agonism in the pharmacology of treating diabetes. |
| doi_str_mv | 10.2337/dbi19-0004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7085250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2340048182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-2835c45063663e04f3378292400fdb38af06fa9a618f169ec2c5a51d954708113</originalsourceid><addsrcrecordid>eNpdkV9LwzAUxYMobk5f_ABS8EWEav61TV-EMXUKA0UUfAtpmnYZbTKTVti3N3NzqOThknt_OZybA8ApgleYkOy6LDTKYwgh3QNDlJM8Jjh73wdDCBGOUZZnA3Dk_SIQaTiHYEAQyhgleAhmL2ppve60NdrU0bTppaiticZy3Yq0ibq5ip7nK69tY-tVJEwZrsK1Qm4atoputShUp_wxOKhE49XJto7A2_3d6-Qhnj1NHyfjWSwpTLsYM5JImsCUpClRkFZhCYZzTCGsyoIwUcG0ErlIEatQmiuJZSISVOYJzSBDiIzAzUZ32RetKqUynRMNXzrdCrfiVmj-d2L0nNf2k4fnCU5gELjYCjj70Svf8VZ7qZpGGGV7zzEJXihDDAf0_B-6sL0zYb1AsYyyLAlfPgKXG0o6671T1c4MgnwdEv8Oia9DCvDZb_s79CcV8gU13Yvw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2387487519</pqid></control><display><type>article</type><title>Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Finan, Brian ; Capozzi, Megan E ; Campbell, Jonathan E</creator><creatorcontrib>Finan, Brian ; Capozzi, Megan E ; Campbell, Jonathan E</creatorcontrib><description>Glucagon is historically described as the counterregulatory hormone to insulin, induced by fasting/hypoglycemia to raise blood glucose through action mediated in the liver. However, it is becoming clear that the biology of glucagon is much more complex and extends beyond hepatic actions to exert control on glucose metabolism. We discuss the inconsistencies with the canonical view that glucagon is primarily a hyperglycemic agent driven by fasting/hypoglycemia and highlight the recent advances that have reshaped the metabolic role of glucagon. These concepts are placed within the context of both normal physiology and the pathophysiology of disease and then extended to discuss emerging strategies that incorporate glucagon agonism in the pharmacology of treating diabetes.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/dbi19-0004</identifier><identifier>PMID: 31178432</identifier><language>eng</language><publisher>United States: American Diabetes Association</publisher><subject>Blood glucose ; Blood Glucose - metabolism ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - metabolism ; Fasting ; Glucagon ; Glucagon - metabolism ; Glucose ; Glucose metabolism ; Humans ; Hyperglycemia ; Hypoglycemia ; Hypoglycemia - metabolism ; Insulin ; Insulin - metabolism ; Liver - metabolism ; Physiology ; Symposium</subject><ispartof>Diabetes (New York, N.Y.), 2020-04, Vol.69 (4), p.532-541</ispartof><rights>2019 by the American Diabetes Association.</rights><rights>Copyright American Diabetes Association Apr 1, 2020</rights><rights>2019 by the American Diabetes Association. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-2835c45063663e04f3378292400fdb38af06fa9a618f169ec2c5a51d954708113</citedby><cites>FETCH-LOGICAL-c406t-2835c45063663e04f3378292400fdb38af06fa9a618f169ec2c5a51d954708113</cites><orcidid>0000-0003-4358-6331</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085250/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085250/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31178432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Finan, Brian</creatorcontrib><creatorcontrib>Capozzi, Megan E</creatorcontrib><creatorcontrib>Campbell, Jonathan E</creatorcontrib><title>Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes</title><title>Diabetes (New York, N.Y.)</title><addtitle>Diabetes</addtitle><description>Glucagon is historically described as the counterregulatory hormone to insulin, induced by fasting/hypoglycemia to raise blood glucose through action mediated in the liver. However, it is becoming clear that the biology of glucagon is much more complex and extends beyond hepatic actions to exert control on glucose metabolism. We discuss the inconsistencies with the canonical view that glucagon is primarily a hyperglycemic agent driven by fasting/hypoglycemia and highlight the recent advances that have reshaped the metabolic role of glucagon. These concepts are placed within the context of both normal physiology and the pathophysiology of disease and then extended to discuss emerging strategies that incorporate glucagon agonism in the pharmacology of treating diabetes.</description><subject>Blood glucose</subject><subject>Blood Glucose - metabolism</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - metabolism</subject><subject>Fasting</subject><subject>Glucagon</subject><subject>Glucagon - metabolism</subject><subject>Glucose</subject><subject>Glucose metabolism</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hypoglycemia</subject><subject>Hypoglycemia - metabolism</subject><subject>Insulin</subject><subject>Insulin - metabolism</subject><subject>Liver - metabolism</subject><subject>Physiology</subject><subject>Symposium</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV9LwzAUxYMobk5f_ABS8EWEav61TV-EMXUKA0UUfAtpmnYZbTKTVti3N3NzqOThknt_OZybA8ApgleYkOy6LDTKYwgh3QNDlJM8Jjh73wdDCBGOUZZnA3Dk_SIQaTiHYEAQyhgleAhmL2ppve60NdrU0bTppaiticZy3Yq0ibq5ip7nK69tY-tVJEwZrsK1Qm4atoputShUp_wxOKhE49XJto7A2_3d6-Qhnj1NHyfjWSwpTLsYM5JImsCUpClRkFZhCYZzTCGsyoIwUcG0ErlIEatQmiuJZSISVOYJzSBDiIzAzUZ32RetKqUynRMNXzrdCrfiVmj-d2L0nNf2k4fnCU5gELjYCjj70Svf8VZ7qZpGGGV7zzEJXihDDAf0_B-6sL0zYb1AsYyyLAlfPgKXG0o6671T1c4MgnwdEv8Oia9DCvDZb_s79CcV8gU13Yvw</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Finan, Brian</creator><creator>Capozzi, Megan E</creator><creator>Campbell, Jonathan E</creator><general>American Diabetes Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4358-6331</orcidid></search><sort><creationdate>20200401</creationdate><title>Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes</title><author>Finan, Brian ; Capozzi, Megan E ; Campbell, Jonathan E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-2835c45063663e04f3378292400fdb38af06fa9a618f169ec2c5a51d954708113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Blood glucose</topic><topic>Blood Glucose - metabolism</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - metabolism</topic><topic>Fasting</topic><topic>Glucagon</topic><topic>Glucagon - metabolism</topic><topic>Glucose</topic><topic>Glucose metabolism</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hypoglycemia</topic><topic>Hypoglycemia - metabolism</topic><topic>Insulin</topic><topic>Insulin - metabolism</topic><topic>Liver - metabolism</topic><topic>Physiology</topic><topic>Symposium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Finan, Brian</creatorcontrib><creatorcontrib>Capozzi, Megan E</creatorcontrib><creatorcontrib>Campbell, Jonathan E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Finan, Brian</au><au>Capozzi, Megan E</au><au>Campbell, Jonathan E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><addtitle>Diabetes</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>69</volume><issue>4</issue><spage>532</spage><epage>541</epage><pages>532-541</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Glucagon is historically described as the counterregulatory hormone to insulin, induced by fasting/hypoglycemia to raise blood glucose through action mediated in the liver. However, it is becoming clear that the biology of glucagon is much more complex and extends beyond hepatic actions to exert control on glucose metabolism. We discuss the inconsistencies with the canonical view that glucagon is primarily a hyperglycemic agent driven by fasting/hypoglycemia and highlight the recent advances that have reshaped the metabolic role of glucagon. These concepts are placed within the context of both normal physiology and the pathophysiology of disease and then extended to discuss emerging strategies that incorporate glucagon agonism in the pharmacology of treating diabetes.</abstract><cop>United States</cop><pub>American Diabetes Association</pub><pmid>31178432</pmid><doi>10.2337/dbi19-0004</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-4358-6331</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2020-04, Vol.69 (4), p.532-541 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7085250 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Blood glucose Blood Glucose - metabolism Diabetes Diabetes mellitus Diabetes Mellitus - metabolism Fasting Glucagon Glucagon - metabolism Glucose Glucose metabolism Humans Hyperglycemia Hypoglycemia Hypoglycemia - metabolism Insulin Insulin - metabolism Liver - metabolism Physiology Symposium |
| title | Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T05%3A51%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repositioning%20Glucagon%20Action%20in%20the%20Physiology%20and%20Pharmacology%20of%20Diabetes&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=Finan,%20Brian&rft.date=2020-04-01&rft.volume=69&rft.issue=4&rft.spage=532&rft.epage=541&rft.pages=532-541&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/dbi19-0004&rft_dat=%3Cproquest_pubme%3E2340048182%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2387487519&rft_id=info:pmid/31178432&rfr_iscdi=true |